China Medical System Holdings Limited, a prominent player in pharmaceutical innovation and commercialisation, has successfully debuted on the Mainboard of the Singapore Exchange (SGX-ST), marking its secondary listing after its initial public offering on the Hong Kong Stock Exchange in 2010. On its first trading day, CMS shares rose by 11.2%, closing at S$2.28, reflecting strong investor confidence in the company’s growth prospects.
The company, which has a market capitalisation of HK$31.91b, is leveraging its 30-year track record in China to expand its footprint across the Asia-Pacific region. CMS’s strategy is driven by three growth engines: the commercialisation of its innovative product pipeline, growth in its speciality-focused business, and overseas expansion to capture opportunities in emerging markets.
CMS’s portfolio includes around 40 innovative products, with five drugs already in large-scale commercialisation in China. The company plans to spin off its skin health business, Dermavon, and list it on the Hong Kong Stock Exchange, highlighting its strong growth momentum.
The listing on SGX-ST is seen as a strategic move to enhance CMS’s brand visibility and support its industrial internationalisation strategy. The company has established a full-scale pharmaceutical value chain in Singapore, aiming to deliver high-quality, affordable drugs to emerging markets.
CMS is optimistic about the growth potential in Southeast Asia and the Middle East, regions projected to see significant pharmaceutical market expansion. The company has also established Rxilient to drive drug in-licensing and commercialisation across Asia-Pacific and co-acquired PharmaGend to bolster its supply chain.
Looking forward, CMS plans to expand its manufacturing capabilities and continue its trajectory of growth in innovative drug development and overseas expansion, aiming to generate incremental value for shareholders.
“`
